NCT02362529View on ClinicalTrials.gov

Biomarkers of Neuroinflammation and Anti-Inflammatory Treatments in Major Depressive Disorder

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

115

Participants

Timeline

Start Date

February 28, 2015

Primary Completion Date

April 30, 2019

Study Completion Date

April 30, 2019

Conditions
Major Depressive Disorder
Interventions
DRUG

Minocycline

50 mg and 100 mg capsule, oral administration

DRUG

Placebo

Lactose monohydrate in identical gel capsules to minocycline, oral administration.

DRUG

Celecoxib

100 mg and 200 mg capsules, oral administration.

Trial Locations (1)

M5T 1R8

Centre for Addiction and Mental Health, Toronto

All Listed Sponsors
lead

Centre for Addiction and Mental Health

OTHER

NCT02362529 - Biomarkers of Neuroinflammation and Anti-Inflammatory Treatments in Major Depressive Disorder | Biotech Hunter | Biotech Hunter